Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with HypertensionA Randomized, Open-Label, Parallel-Group, Multicentre,Dose-Escalation Study with an Extension Phase

被引：0
|
作者：
Domenic Sica
Alan H. Gradman
Ole Lederballe
Rainer E. Kolloch
Jack Zhang
Deborah L. Keefe
机构：
[1] Virginia Commonwealth University Health System,Clinical Development and Medical Affairs
[2] The Western Pennsylvania Hospital,undefined
[3] Regionshospitalet Viborg,undefined
[4] Evangelisches Krankenhaus Bielefeld and University of Munster,undefined
[5] Mediziniche Klinik Gilead,undefined
[6] Novartis Pharmaceuticals Corporation,undefined
[7] One Health Plaza,undefined
[8] Novartis Pharmaceuticals Corporation,undefined
来源：
Clinical Drug Investigation | 2011年 / 31卷
关键词：
Plasma Renin Activity; Aliskiren; HCTZ; Thiazide Diuretic; Core Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Most patients with hypertension will require combination therapy with at least two agents from different antihypertensive classes to achieve blood pressure (BP) control. Thiazide diuretics, such as hydrochlorothiazide (HCTZ), are widely used in combination therapy. The volume reduction with these agents stimulates the renin-angiotensin system (RAS), making RAS inhibitors such as the direct renin inhibitor aliskiren a logical choice for combination therapy with HCTZ.
引用
收藏
页码：825 / 837
页数：12
相关论文
共 50 条
  • [1] Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase
    Sica, Domenic
    Gradman, Alan H.
    Lederballe, Ole
    Kolloch, Rainer E.
    Zhang, Jack
    Keefe, Deborah L.
    CLINICAL DRUG INVESTIGATION, 2011, 31 (12) : 825 - 837
  • [2] Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
    Imamura, Keiko
    Izumi, Yuishin
    Nagai, Makiko
    Nishiyama, Kazutoshi
    Watanabe, Yasuhiro
    Hanajima, Ritsuko
    Egawa, Naohiro
    Ayaki, Takashi
    Oki, Ryosuke
    Fujita, Koji
    Uozumi, Ryuji
    Morinaga, Akiko
    Hirohashi, Tomoko
    Fujii, Yosuke
    Yamamoto, Takuya
    Tatebe, Harutsugu
    Tokuda, Takahiko
    Takahashi, Naoto
    Morita, Satoshi
    Takahashi, Ryosuke
    Inoue, Haruhisa
    ECLINICALMEDICINE, 2022, 53
  • [3] Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study
    Arai, Hidenori
    Yamashita, Shizuya
    Araki, Eiichi
    Yokote, Koutaro
    Tanigawa, Ryohei
    Saito, Ayumi
    Furukawa, Daisuke
    Suganami, Hideki
    Ishibashi, Shun
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2025,
  • [4] Long Term Outcomes of a Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)
    Hendriksz, Christian
    Vellodi, Ashok
    Jones, Simon
    Takkele, Hiwot
    Lee, S.
    Chesler, Sarah
    Decker, Celeste
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S35 - S35
  • [5] Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
    Kadowaki, Takashi
    Chin, Rina
    Ozeki, Akichika
    Imaoka, Takeshi
    Ogawa, Yoshihiro
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (09): : 634 - 644
  • [6] Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
    Ferrannini, Ele
    Berk, Andreas
    Hantel, Stefan
    Pinnetti, Sabine
    Hach, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2013, 36 (12) : 4015 - 4021
  • [7] LONG-TERM SAFETY AND TOLERABILITY OF ORAL TOFACITINIB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM A PHASE 2 OPEN-LABEL 48-WEEK EXTENSION STUDY
    Panes, Julian
    D'Haens, Geert R.
    Higgins, Peter D.
    Mele, Linda
    Moscariello, Michele
    Chan, Gary
    Wang, Wenjin
    Niezychowski, Wojciech
    Su, Chinyu
    Maller, Eric S.
    GASTROENTEROLOGY, 2017, 152 (05) : S599 - S599
  • [8] Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study
    Panes, Julian
    D'Haens, Geert R.
    Higgins, Peter D. R.
    Mele, Linda
    Moscariello, Michele
    Chan, Gary
    Wang, Wenjin
    Niezychowski, Wojciech
    Su, Chinyu
    Maller, Eric
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (03) : 265 - 276
  • [9] Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study
    Panes, J.
    D'Haens, G. R.
    Higgins, P. D. R.
    Mele, L.
    Moscariello, M.
    Chan, G.
    Wang, W.
    Niezychowski, W.
    Su, C.
    Maller, E.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S18 - S19
  • [10] Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy
    Usui, Naotaka
    Akamatsu, Naoki
    Nakasato, Nobukazu
    Ohnishi, Akihiro
    Kaneko, Sunao
    Hiramatsu, Hidetaka
    Saeki, Kazunori
    Miyagishi, Hideaki
    Inoue, Yushi
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2018, 62 : 26 - 32
12345